News › Clinical Practice, Industry News, Patient Care

FDA Approves Zepbound for Treatment of Obstructive Sleep Apnea

January 2, 2025

On December 20, the U.S. Food and Drug Administration approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity, to be used in combination with a reduced-calorie diet and increased physical activity.

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical Care in the FDA’s Center for Drug Evaluation and Research. “This is a major step forward for patients with obstructive sleep apnea.”

OSA occurs when a person’s upper airway becomes blocked, causing pauses in breathing during sleep. While OSA can affect anyone, it is more common in people who have overweight or obesity. Zepbound works by activating receptors of hormones secreted from the intestine (glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)) to reduce appetite and food intake. By reducing body weight, studies show that Zepbound also improves OSA.

Read more at U.S. FDA >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Raging Agency Becomes Silver Vendor Affiliate with the American Med Spa Association
    • Medical Marketing Whiz Announces Partnership With Boulevard to Help Med Spas and Wellness Clinics Streamline Operations
    • ByrdAdatto Attorneys Recognized in the 2027 Edition of Best Lawyers
    • RHA Redensity Eye Receives FDA Approval for Undereye Hollowing
    • South Carolina Medical Board Warns Against Use of Research-Grade Peptides
Advertisement